Strive for the
Full Picture
Peptides are everywhere right now, and source matters more than ever. Strive only compounds peptides eligible for compounding under Section 503A, and we'll expand as the FDA eligibility is established.
Not a Strive provider yet?
Where Peptides
Stand Today:
On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee (PCAC) wrapped its review of seven peptide substances for the 503A Bulks List. Six of them, BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, received favorable committee votes.
Here's what that means (and doesn't): a PCAC vote is a recommendation, not a ruling. It's a strong signal, the kind that's historically carried real weight with the FDA, but it's not the finish line. No final decision has been made, and nothing changes for compounding eligibility until the FDA acts.
That's exactly the kind of unclear path Strive was built to navigate. We've spent years exploring peptide formulation and development, validated sourcing, and quality testing, so we're not starting from zero; we're prepared to move forward for patients and providers the moment the FDA establishes a clear framework.
The next phase of peptide compounding should be built on consistent, verifiable quality, batch-to-batch consistency, and full transparency in sourcing, standards, and documentation. Availability alone isn't the goal; trust is.
Learn More
Strive Pharmacy and the
Read More
Future of Peptides
Strive Sessions Recap:
Learn More
Peptides
Not Yet a Strive
Provider?
Want Access to Strive's Full Catalog?
Peptides are one part of a much bigger picture. If you're not yet a Strive provider, this is a good moment to talk. Our existing formulations, support model, and quality systems are available to partner providers, for compounding upon receipt of a valid prescription, regardless of where peptides land.
Stay in the Know
Be the first to know when peptide eligibility status changes, and get education as it's released.
Compounded medications are specially prepared for identified individual patient needs based on a valid prescription from a prescribing healthcare practitioner and, as such, are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety or efficacy. Compounded drugs are intended for patients whose prescriber has determined their medical needs are not met by an available FDA-approved drug. These statements have not been evaluated by the FDA.